MiNK Therapeutics Files 2025 Proxy Statement
Ticker: INKT · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1840229
Sentiment: neutral
Topics: proxy-statement, corporate-governance, executive-compensation
TL;DR
MiNK files proxy statement for 2024, shareholders vote on exec pay & board.
AI Summary
MiNK Therapeutics, Inc. filed its definitive proxy statement on April 30, 2025, for the fiscal year ending December 31, 2024. The company, formerly known as AgenTus Therapeutics, Inc. until January 12, 2021, is seeking shareholder approval for matters related to its annual meeting. The filing details executive compensation, board nominations, and other corporate governance issues.
Why It Matters
This filing provides shareholders with crucial information regarding the company's leadership, compensation, and strategic direction, enabling informed voting decisions.
Risk Assessment
Risk Level: medium — Proxy statements often contain information about executive compensation, board composition, and potential shareholder proposals that can indicate areas of focus or potential conflict.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former company name
- 2024-12-31 (date) — Fiscal year end
- 2025-04-30 (date) — Filing date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the annual meeting, including details on executive compensation, board nominations, and other corporate governance matters.
When is MiNK Therapeutics' fiscal year end?
MiNK Therapeutics' fiscal year ends on December 31st.
What was MiNK Therapeutics' former name?
MiNK Therapeutics, Inc. was formerly known as AgenTus Therapeutics, Inc.
On what date was this definitive proxy statement filed?
This definitive proxy statement was filed on April 30, 2025.
What is the company's primary business classification?
The company's Standard Industrial Classification is Biological Products (No Diagnostic Substances) [2836].
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding MiNK Therapeutics, Inc. (INKT).